Premium
The Efficacy of Bone Morphogenetic Protein‐2 Depends on Its Mode of Delivery
Author(s) -
La WanGeun,
Kang SunWoong,
Yang Hee Seok,
Bhang Suk Ho,
Lee Sun Hwa,
Park JungHo,
Kim ByungSoo
Publication year - 2010
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.2009.00988.x
Subject(s) - bone morphogenetic protein , bone morphogenetic protein 2 , delivery system , drug delivery , chemistry , bone formation , biomedical engineering , medicine , biochemistry , in vitro , organic chemistry , gene
Bone morphogenetic protein‐2 (BMP‐2) induces bone regeneration in a dose‐dependent manner, with higher doses of BMP‐2 inducing greater bone formation. Previously, we showed that long‐term delivery of BMP‐2 provides better ectopic bone formation than short‐term delivery of an equivalent dose. In the present study, we investigated the efficacy of orthotopic bone formation over a range of BMP‐2 doses, using different delivery modes. Heparin‐conjugated poly(lactic‐co‐glycolic acid) nanospheres suspended in fibrin gel were used as a long‐term delivery system, and fibrin gel was used as a short‐term delivery system. Different doses of BMP‐2 were delivered to mouse calvarial defects using either long‐term or short‐term delivery systems. Eight weeks after treatment, bone regeneration was evaluated by histomorphometry. For both delivery systems, bone regeneration increased as the BMP‐2 dose increased up to 1 µg and did not increase beyond this dose. Importantly, at BMP‐2 doses higher than 1 µg, long‐term delivery resulted in much greater bone formation than short‐term delivery. This study shows that long‐term delivery of BMP‐2 is more effective at enhancing orthotopic bone formation than short‐term delivery over a range of doses.